香港市場銘柄情報

01530 三生製薬

銘柄追加

6.800
+0.220+3.34%

取引時間外 05/03 16:09 CST

165.85億時価総額9.70直近PER

三生製薬に関するコメント

ログインコメントを投稿

Moomoo AI

03/18 09:08

3SBio Inc.'s lower P/E ratio is due to its forecasted growth being less than the wider market. The potential for earnings improvement may not justify a higher P/E ratio, forming a barrier for the share price.

Investors Don't See Light At End Of 3SBio Inc.'s (HKG:1530) Tunnel

Moomoo AI

01/24 15:50

Despite a recent drop, 3SBio's strong financials and high ROE could boost stock value long term. Significant earnings growth due to substantial profit reinvestment, though future growth may slow.

Could The Market Be Wrong About 3SBio Inc. (HKG:1530) Given Its Attractive Financial Prospects?

Moomoo AI

2023/12/29 07:33

Analyst indicates that the investment risk in 3SBio is kept in check by net cash and EBIT growth. Even though managing debt could be challenging as free cash flow was only 46% of EBIT recently, the company's financials are still strong.

3SBio (HKG:1530) Seems To Use Debt Rather Sparingly

Moomoo AI

2023/12/08 06:19

3SBio, with EPS growth and increased EBIT margins, is defined as a growing business. High level of insider ownership is deemed positive, aligning with shareholders' interests. Yet, the market valuation of it remains unanalysed.

3SBio (HKG:1530) Ticks All The Boxes When It Comes To Earnings Growth

Moomoo AI

2023/11/14 06:44

Despite positive revenue and earnings growth, 3SBio's falling share price signals potential lack of investor faith or unfulfilled market expectations.